OCCURRENCE AND MANAGEMENT OF UREMIC CARDIOMYOPATHY

A questionnaire based study was carried on 50 patients suffering from uremic cardiomyopathy. The patients were selected randomly at Mayo hospital and Sheikh Zaid hospital, Lahore. The aims and objectives of the study were to identify the occurrence and management of uremic cardiomyopathy. Uremic cardiomyopathy is the condition of left ventricular hypertrophy, left ventricular dilatation or LV systolic dysfunction and it is reported to be a leading cause of premature cardiovascular mortality in patients with end-stage renal disease the medication given was beta blockers and ca-channel blockers. Dialysis is an alternative medical treatment option for many people living without functioning kidneys. Frequent hemodialysis is associated with less dialysis-induced hypotension and myocardial stunning compared with conventional hemodialysis. Dialysis patients often require multiple pharmacotherapies and complicated drug regimens to manage their conditions. They have increased risk of drug adverse events and drug complications. Key words: Left ventricular hypertrophy; Left ventricular dilation; end-stage renal disease; chronic kidney disease;